Rich Pharmaceuticals Attracts New Financing Package with

New Post Public Reply Private Reply Replies (0) Message Board
mick
1,037
Rich Pharmaceuticals Attracts New Financing Package with GHS Investments, LLC

BEVERLY HILLS, Calif., Feb. 28, 2017 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich" or the "Company" , a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology announced today that it has entered into new financing agreements with GHS Investments, LLC.



The investments will be made through an equity purchase agreement and registration rights agreement that provides for the sale of up to $2 million in shares of the Company's common stock to GHS Investments, LLC. The obligations of GHS Investments, LLC to purchase the shares are subject to certain conditions contained in the financing agreements, including the filing of a registration statement with the Securities and Exchange Commission and the effectiveness of the registration statement. CEO of Rich Pharmaceuticals, Ben Chang, stated "We are excited to start our new partnership with GHS Investments and believe this will be a step in the right direction while we continue our efforts in the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS). This is a crucial move because once the registration statement is effective it will allow funding while the Company begins clinical trials." "We believe that a financing that is equity based and allows the Company to decide when shares are issued will allow us to move in the right direction" continued Mr. Chang.

Rich Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology. The company is in Phase 1/2 clinical trials for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS).

The terms of the equity purchase agreement and registration rights agreement, and copies of those agreements, were disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 27, 2017, which may be found at www.sec.gov or on the Company's website at www.richpharmaceuticals.com/investor-relations/sec-filings/.

Forward-Looking Statements:
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, and our ability to obtain financing from GHS Investments. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to commence clinical trials and to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.

Investor Relations:
9595 Wilshire Blvd., Suite 900
Beverly Hills, CA 90212
IR@richph.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rich-pharmaceuticals-attracts-new-financing-package-with-ghs-investments-llc-300414675.html

SOURCE Rich Pharmaceuticals, Inc.


News Provided by QuoteMedia.

Rich Pharmaceuticals, Inc. (RCHA) Stock Research Links

RCHA Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carbonization Furnaces Turn Waste Rules Into Demand

Updated Category News Views 84

Smoke has become an expensive habit for farmers, mills, and municipalities. That is the real commercial backdrop for carbonization furnaces, not some glossy green-tech slogan. MarketsandMarkets estimates this small global equipment market at $310 million in 2026 and projects $510 million by 2031, a 10.2% compound annual growth rate. For a capital-equipment niche, that is...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 104

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
Mindstream’s Jordan AI Campus Faces Its First Real Test

Updated Category News Views 31

Jordan’s AI ambitions just got attached to a very large gas meter. Mindstream Energy has unveiled a plan for an AI-ready data-center campus at Al-Risha in Mafraq Governorate, built around dedicated natural-gas generation rather than a conventional dependence on the utility grid. The headline number is 400 megawatts of eventual capacity. The number that matters first is...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 74

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes

Updated Category News Views 123

A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 71

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 144

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 143

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 166

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Makera A1S Tests the Desktop CNC Metal-Cutting Promise

Updated Category News Views 61

Aluminum chips are where desktop-machine marketing stops bluffing, and Makera is leaning right into that test with the A1S. The company opened global pre-orders on November 18 for a machine aimed squarely at the awkward middle ground: users who have outgrown entry-level hobby gear but do not have room, budget, or patience for a full industrial setup. That is a real market...

Continue Reading

Top 5 Most Recently Viewed Articles

Future Growth of the Premium Chocolate Sector: Insights and Trends

Updated Category News Views 85

An Insight into the Premium Chocolate Market The global premium chocolate market is experiencing remarkable growth, with projections indicating an increase of USD 20.8 billion between 2024 and 2028. This growth is expected to occur at a compound annual growth rate (CAGR) of 9.48%. Key drivers for this rise encompass new product launches and evolving consumer preferences....

Continue Reading
Lovesac's Commitment to Sustainability: The 2024 ESG Report

Updated Category News Views 260

Understanding Lovesac's 2024 ESG Report The Lovesac Company (NASDAQ: LOVE) has recently published its Environmental, Social, and Governance (ESG) Report for the fiscal year ending February 4, 2024. This comprehensive report showcases the company’s unwavering commitment to sustainability and responsible business practices, emphasizing their innovative product offerings...

Continue Reading
How High-Net-Worth Investors Can Save Millions in Taxes

Updated Category News Views 171

Strategies for High-Net-Worth Investors to Manage Tax Implications In a world where technology and artificial intelligence are reshaping the investment landscape, the CEO of Wealthstone, Zak Gardezy, offers new insights for high-net-worth individuals. His recent publication, Secrets of a Wealth Advisor: How To Diversify Concentrated Stock Tax Efficiently, focuses on...

Continue Reading
Major Leadership Change at Camping World Holdings Inc. Revealed

Updated Category News Views 251

Marcus Lemonis Steps Down from Camping World Holdings Inc. Marcus Lemonis, a prominent entrepreneur and television personality famed for his roles in popular shows, has announced his departure as CEO of Camping World Holdings Inc. (NYSE: CWH). This announcement marks a significant change for the company Lemonis co-founded, which has grown into a leading name in the...

Continue Reading
Market Outlook Update: Novozymes' Stock Rating Downgrade

Updated Category News Views 131

Recent Downgrade of Novozymes Stock by Citi Novozymes A/S (OTC: NVZMY) recently faced a significant shift in its market perception as Citi has downgraded the company’s stock rating from Neutral to Sell. Even with this downgrade, the price target has seen a slight improvement—from DKK390.00 to DKK400.00. This change arrives despite the company showcasing a remarkable...

Continue Reading